NXY-059. Centaur.
Centaur and AstraZeneca are developing NXY-059, an alpha-phenyl-N-tert-butyl nitrone derivative, free radical trapping agent, for the potential therapy of reperfusion injury following stroke. Phase II clinical trials are ongoing, with phase III trials in acute stroke planned for initiation in early 2003.
Lapchak
Paul A
PA
UCSD Neuroscience MTF 316, 9500 Gilman Drive, La Jolla, CA 92093-0624, USA. plapchak@ucsd.edu
D000818:Animals; D001557:Benzenesulfonates; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D004345:Drug Industry / Q000331:legislation & jurisprudence / Q000379:methods*; D006801:Humans; D009589:Nitrogen Oxides / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D020521:Stroke / Q000188:drug therapy
D001557:Benzenesulfonates; D009589:Nitrogen Oxides; C120851:disufenton sodium